{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:53:19Z","timestamp":1791298399148,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016939","name":"Myriad Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016939","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Young age at breast cancer (BC) diagnosis and family history of BC are strongly associated with high prevalence of pathogenic variants (PVs) in <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> genes. There is limited evidence for such associations with moderate\/high penetrance BC-risk genes such as <jats:italic>ATM<\/jats:italic>, <jats:italic>CHEK2<\/jats:italic>, and <jats:italic>PALB2<\/jats:italic>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed multi-gene panel testing results (09\/2013\u201312\/2019) for women unaffected by any cancer (N\u2009=\u2009371,594) and those affected with BC (N\u2009=\u2009130,151) ascertained for suspicion of hereditary breast and\/or ovarian cancer. Multivariable logistic regression was used to test association between PV status and age at BC diagnosis (\u2264\u200945 vs.\u2009&gt;\u200945\u00a0years) or family history of BC after controlling for personal\/family non-BC histories and self-reported ancestry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>An association between young age (\u2264\u200945\u00a0years) at diagnosis and presence of PVs was strong for <jats:italic>BRCA1<\/jats:italic> (OR 3.95, 95% CI 3.64\u20134.29) and moderate for <jats:italic>BRCA2<\/jats:italic> (OR 1.98, 95% CI 1.84\u20132.14). Modest associations were observed between PVs and young age at diagnosis for <jats:italic>ATM<\/jats:italic> (OR 1.22, 95% CI 1.08\u20131.37) and <jats:italic>CHEK2<\/jats:italic> (OR 1.34, 95% CI 1.21\u20131.47) genes, but not for <jats:italic>PALB2<\/jats:italic> (OR 1.12, 95% CI 0.98\u20131.27). For women with BC, earliest age of familial BC diagnosis followed a similar pattern. For unaffected women, earliest age of family cancer diagnosis was significantly associated with PV status only for <jats:italic>BRCA1<\/jats:italic> (OR 2.34, 95% CI 2.13\u20132.56) and <jats:italic>BRCA2<\/jats:italic> (OR 1.25, 95% CI 1.16\u20131.35).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Young age at BC diagnosis is not a strong risk factor for carrying PVs in BC-associated genes <jats:italic>ATM, CHEK2,<\/jats:italic> or <jats:italic>PALB2<\/jats:italic>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-023-06946-8","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T09:08:33Z","timestamp":1682068113000},"page":"617-626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The association between age at breast cancer diagnosis and prevalence of pathogenic variants"],"prefix":"10.1007","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7490-6038","authenticated-orcid":false,"given":"Mary B.","family":"Daly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Bernhisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisha","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Meek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison W.","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"6946_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","volume":"5182","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 5182:66\u201371","journal-title":"Science"},{"key":"6946_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/ng0396-333","volume":"3","author":"S Tavtigian","year":"1996","unstructured":"Tavtigian S, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S et al (1996) The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 3:333\u2013337","journal-title":"Nat Genet"},{"key":"6946_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","volume":"15","author":"AW Kurian","year":"2019","unstructured":"Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A et al (2019) Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol 15:1305","journal-title":"J Clin Oncol"},{"key":"6946_CR4","unstructured":"Daly, MB, Pal, T, AlHilli, Z, Arun, B, Buys, SS, Cheng, H, et al. NCCN Clinical practice guidelines in oncology, genetic\/familial high-risk assessment: breast, ovarian, and pancreatic (Version 1.2023). NCCN Clinical Practice Guidelines in Oncology 2023; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf. Accessed 22 February 2023."},{"key":"6946_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.29010","volume":"1","author":"N Tung","year":"2015","unstructured":"Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K et al (2015) Frequency of mutations in individuals with breast cancer referred for BRCA 1 and BRCA 2 testing using next-generation sequencing with a 25-gene panel. Cancer 1:25\u201333","journal-title":"Cancer"},{"key":"6946_CR6","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.6004\/jnccn.2014.0128","volume":"9","author":"MJ Hall","year":"2014","unstructured":"Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN (2014) Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw 9:1339\u20131346","journal-title":"J Natl Compr Canc Netw"},{"key":"6946_CR7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","volume":"7","author":"A Desmond","year":"2015","unstructured":"Desmond A, Kurian AW, Gabree M, Mills MA, Anderson MJ, Kobayashi Y et al (2015) Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol 7:943\u2013951","journal-title":"JAMA Oncol"},{"key":"6946_CR8","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1245\/s10434-015-4754-2","volume":"10","author":"NS Kapoor","year":"2015","unstructured":"Kapoor NS, Curcio LD, Blakemore CA, Bremner AK, McFarland RE, West JG, Banks KC (2015) Multigene panel testing detects equal rates of pathogenic BRCA1\/2 mutations and has a higher diagnostic yield compared to limited BRCA1\/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol 10:3282\u20133288","journal-title":"Ann Surg Oncol"},{"key":"6946_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/gim.2014.176","volume":"8","author":"KN Maxwell","year":"2015","unstructured":"Maxwell KN, Wubbenhorst B, D\u2019Andrea K, Garman B, Long JM, Powers J et al (2015) Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1\/2-negative patients with early-onset breast cancer. Genet Med 8:630\u2013638","journal-title":"Genet Med"},{"key":"6946_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.30498","volume":"10","author":"SS Buys","year":"2017","unstructured":"Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL et al (2017) A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 10:1721\u20131730","journal-title":"Cancer"},{"key":"6946_CR11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"9","author":"FJ Couch","year":"2017","unstructured":"Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J et al (2017) Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol 9:1190\u20131196","journal-title":"JAMA Oncol"},{"key":"6946_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2017.09.003","author":"ET Rosenthal","year":"2017","unstructured":"Rosenthal ET, Bernhisel R, Brown K, Kidd J, Manley S (2017) Clinical testing with a panel of 25 genes associated with increased cancer risk results in a significant increase in clinically significant findings across a broad range of cancer histories. Cancer Genet. https:\/\/doi.org\/10.1016\/j.cancergen.2017.09.003","journal-title":"Cancer Genet"},{"key":"6946_CR13","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamaoncol.2018.0644","volume":"8","author":"AW Kurian","year":"2018","unstructured":"Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I et al (2018) Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol 8:1066\u20131072","journal-title":"JAMA Oncol"},{"key":"6946_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10549-017-4181-0","volume":"2","author":"B Crawford","year":"2017","unstructured":"Crawford B, Adams SB, Sittler T, van den Akker J, Chan S, Leitner O et al (2017) Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients. Breast Cancer Res Treat 2:383\u2013390","journal-title":"Breast Cancer Res Treat"},{"key":"6946_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/gim.2015.166","volume":"8","author":"LR Susswein","year":"2016","unstructured":"Susswein LR, Marshall ML, Nusbaum R, Postula KJV, Weissman SM, Yackowski L et al (2016) Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med 8:823\u2013832","journal-title":"Genet Med"},{"key":"6946_CR16","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","volume":"10","author":"ER Manahan","year":"2019","unstructured":"Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM et al (2019) Consensus guidelines on genetictesting for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol 10:3025\u20133031","journal-title":"Ann Surg Oncol"},{"key":"6946_CR17","doi-asserted-by":"publisher","first-page":"e196400","DOI":"10.1001\/jamaoncol.2019.6400","volume":"4","author":"AW Kurian","year":"2020","unstructured":"Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Deapen D, Morrow M et al (2020) Association of germline genetic testing results with locoregional and systemic therapy in patients with breast cancer. JAMA Oncol 4:e196400\u2013e196400","journal-title":"JAMA Oncol"},{"key":"6946_CR18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1001\/jama.2020.0229","volume":"10","author":"AW Kurian","year":"2020","unstructured":"Kurian AW, Bernhisel R, Larson K, Caswell-Jin JL, Shadyab AH, Ochs-Balcom H, Stefanick ML (2020) Prevalence of pathogenic variants in cancer susceptibility genes among women with postmenopausal breast cancer. JAMA 10:995\u2013997","journal-title":"JAMA"},{"issue":"31","key":"6946_CR19","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.21.00531","volume":"39","author":"NJ Boddicker","year":"2021","unstructured":"Boddicker NJ, Hu C, Weitzel JN, Kraft P, Nathanson KL, Goldgar DE et al (2021) Risk of late-onset breast cancer in genetically predisposed women. J Clin Oncol JCO. 39(31):3430\u20133440","journal-title":"J Clin Oncol JCO."},{"key":"6946_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"5","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 5:405\u2013423","journal-title":"Genet Med"},{"key":"6946_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/cge.12315","volume":"3","author":"J Eggington","year":"2014","unstructured":"Eggington J, Bowles K, Moyes K, Manley S, Esterling L, Sizemore S et al (2014) A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet 3:229\u2013237","journal-title":"Clin Genet"},{"key":"6946_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00020","author":"L Esterling","year":"2020","unstructured":"Esterling L, Wijayatunge R, Brown K, Morris B, Hughes E, Pruss D et al (2020) Impact of a cancer gene variant reclassification program over a 20-year period. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.20.00020","journal-title":"JCO Precis Oncol"},{"key":"6946_CR23","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1200\/JCO.2017.74.5182","volume":"34","author":"E Mundt","year":"2017","unstructured":"Mundt E, Nix P, Brown K, Bowles KR, Manley S (2017) Complexities of variant classification in clinical hereditary cancer genetic testing. J Clin Oncol 34:3796\u20133799","journal-title":"J Clin Oncol"},{"key":"6946_CR24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10549-020-05543-3","volume":"2","author":"I Rainville","year":"2020","unstructured":"Rainville I, Hatcher S, Rosenthal E, Larson K, Bernhisel R, Meek S et al (2020) High risk of breast cancer in women with biallelic pathogenic variants in CHEK2. Breast Cancer Res Treat 2:503\u2013509","journal-title":"Breast Cancer Res Treat"},{"key":"6946_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/PO.16.00066","author":"AW Kurian","year":"2017","unstructured":"Kurian AW, Hughes E, Handorf E, Gutin A, Allen B, Hartman AR, Hall MJ (2017) Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women. J Clin Oncol Precis Oncol. https:\/\/doi.org\/10.1200\/PO.16.00066","journal-title":"J Clin Oncol Precis Oncol"},{"key":"6946_CR26","first-page":"467","volume":"5","author":"JM Satagopan","year":"2001","unstructured":"Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM et al (2001) The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 5:467\u2013473","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"6946_CR27","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1200\/JCO.19.02190","volume":"13","author":"S Yadav","year":"2020","unstructured":"Yadav S, Hu C, Hart SN, Boddicker N, Polley EC, Na J et al (2020) Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. J Clin Oncol 13:1409","journal-title":"J Clin Oncol"},{"key":"6946_CR28","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/jgs.15937","volume":"5","author":"Y Chavarri-Guerra","year":"2019","unstructured":"Chavarri-Guerra Y, Hendricks CB, Brown S, Marcum C, Hander M, Segota ZE et al (2019) The burden of breast cancer predisposition variants across the age spectrum among 10 000 patients. J Am Geriatr Soc 5:884\u2013888","journal-title":"J Am Geriatr Soc"},{"key":"6946_CR29","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"23","author":"DF Easton","year":"2015","unstructured":"Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL et al (2015) Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 23:2243\u20132257","journal-title":"N Engl J Med"},{"key":"6946_CR30","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"5","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J et al (2021) A population-based study of genes previously implicated in breast cancer. N Engl J Med 5:440\u2013451. https:\/\/doi.org\/10.1056\/NEJMoa2005936","journal-title":"N Engl J Med"},{"key":"6946_CR31","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1200\/JCO.2015.63.7454","volume":"13","author":"ER Thompson","year":"2016","unstructured":"Thompson ER, Rowley SM, Li N, McInerny S, Devereux L, Wong-Brown MW et al (2016) Panel testing for familial breast cancer: calibrating the tension between research and clinical care. J Clin Oncol 13:1455\u20131459","journal-title":"J Clin Oncol"},{"key":"6946_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10689-016-9956-7","volume":"3","author":"S Yadav","year":"2017","unstructured":"Yadav S, Reeves A, Campian S, Paine A, Zakalik D (2017) Outcomes of retesting BRCA negative patients using multigene panels. Fam Cancer 3:319\u2013328","journal-title":"Fam Cancer"},{"key":"6946_CR33","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"7","author":"X Yang","year":"2020","unstructured":"Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B et al (2020) Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol 7:674","journal-title":"J Clin Oncol"},{"key":"6946_CR34","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.20.02785","volume":"15","author":"AW Kurian","year":"2021","unstructured":"Kurian AW, Ward KC, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D et al (2021) Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012\u20132019. J Clin Oncol 15:1631\u20131640","journal-title":"J Clin Oncol"},{"key":"6946_CR35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41436-019-0712-x","volume":"4","author":"T Pal","year":"2020","unstructured":"Pal T, Agnese D, Daly M, La Spada A, Litton J, Wick M et al (2020) Points to consider: is there evidence to support BRCA1\/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 4:681\u2013685","journal-title":"Genet Med"},{"key":"6946_CR36","doi-asserted-by":"publisher","DOI":"10.1200\/po.21.00261","author":"AW Kurian","year":"2021","unstructured":"Kurian AW, Abrahamse P, Ward KC, Hamilton AS, Deapen D, Berek JS et al (2021) Association of family cancer history with pathogenic variants in specific breast cancer susceptibility genes. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/po.21.00261","journal-title":"JCO Precis Oncol"},{"key":"6946_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/jgc4.1250","volume":"4","author":"JM Peterson","year":"2020","unstructured":"Peterson JM, Pepin A, Thomas R, Biagi T, Stark E, Sparks AD et al (2020) Racial disparities in breast cancer hereditary risk assessment referrals. J Genet Couns 4:587\u2013593. https:\/\/doi.org\/10.1002\/jgc4.1250","journal-title":"J Genet Couns"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06946-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-06946-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06946-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T17:55:37Z","timestamp":1683827737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-06946-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["6946"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-06946-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"assertion":[{"value":"4 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eric Rosenthal, Shelly Cummings, Ryan Bernhisel, John Kidd, Elisha Hughes, Stephanie Meek, Thomas P. Slavin were employed by Myriad Genetics at the time of the study and received salary and stock options. Allison Kurian has received funding to institution from Myriad Genetics, Inc. All other authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The analysis described in this manuscript was performed using de-identified data obtained during the course of routine healthcare operations. Only aggregate data are presented in the manuscript. Therefore, this analysis did not meet the U.S. Health and Human Services definition of research on human subjects (HHS 46.102) and did not require Institutional Review Board approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All individuals provided written informed consent for clinical testing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participations"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publications"}}]}}